We only have this paper's title and publication details.
Read it at the sourceResearch reveals EGLN2 reduces malignancy and activates ferroptosis in ovarian cancer, suggesting a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: